Skip to content

Prospective Analysis and Evaluation of freuquency and intensity of migraine, sleeping, Depression and Oxytocin and CGRP-Levels in patients with refractary migraine under noninvasive VNS stimulation

Prospective Analysis and Evaluation of freuquency and intensity of migraine, sleeping, Depression and Oxytocin and CGRP-Levels in patients with refractary migraine under noninvasive VNS stimulation

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
DRKS
Registry ID
DRKS00011089
Enrollment
28
Registered
2016-09-21
Start date
2016-09-23
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

R51 G43

Interventions

Group 1: ARM 1: This is a prospective pilotstudy of 14 patients to investigate the effectiveness of non-invaisve VNS-therapy (25Hz mit 5000Hz Burst) for patients suffering from refractory migraine wit

Sponsors

Funktionelle Neurochirurgie, Stereotaxie und Neuromodulation, Klinik für Neurochirurgie, Universitätsklinikum Bonn
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: - male/femalen - written informed consent - stable headache medication history - Refraktary - Compliance to Follow-Up

Exclusion criteria

Exclusion criteria: -any Kind of historical neuological disease - abuse of drugs - severe psychological disorders - Age below 18, above 60 -history of Neuromodulation

Design outcomes

Primary

MeasureTime frame
-Analysis of Intensity and frequency of headache baseline and after 8 weeks of VNS Stimulation with the MIDAS and the HIT6 scores -Analysis of sleeping disturbances with the PSQI score baseline and after 8 weeks -Analysis of Depression with the BDI score baseline and after 8 weeks -Analysis of laboratory measurements of Oxytocin and CGRP baseline and after 8 weeks

Secondary

MeasureTime frame
Correlation of clinical outcome assessed by the above mentioned scores (MIDAS, HIT6, PSQI, BDI) and changes of oxytocin and CGRP Levels baseline and after 8 weeks of non-invasive VNS therapy.

Countries

Germany

Contacts

Public ContactAzize Boström

Neurochirurgische Klinik,Universitätsklinikum Bonn

azize.bostroem@ukb.uni-bonn.de+49 (0)228 287 - 11349

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026